• About us
    • Awards and certifications
    • History and start-ups
    • Governance
    • Annual report
  • Careers
    • Working at CSEM
    • Jobs
    • Back2Business program
    • Spin-off program
  • Contact us
Our expertise
  • Tailored services
  • How to collaborate with us
  • IP policy and confidentiality
  • European projects
News & more
  • News
  • Events
  • Blog
Press and Publications
  • Press room
  • Downloads
  • YODA Open access platform
About us
  • Awards and certifications
  • History and start-ups
  • Governance
  • Annual report
Careers
  • Working at CSEM
  • Jobs
  • Back2Business program
  • Spin-off program
Contact us
  • Our expertise
    • Technical focus
      • Additive manufacturing
      • ASICs for the edge
      • Batteries
      • Data and AI
      • Digital energy
      • Digital health
      • Functional surfaces
      • Industry 4.0
      • Integrated and lightweight photovoltaics
      • IoT and vision
      • MEMS
      • Photonics
      • Quantum technologies
      • Scientific instruments
      • Solar cells and modules
      • Tools for life sciences
    • Industrial focus
      • Automotive and transportation
      • Consumer electronics
      • Energy
      • Environment
      • Food and agriculture
      • Healthcare, wellness and sport
      • Industrial automation
      • Information and Communication Technologies
      • Life sciences
      • Security and safety
      • Semiconductors
      • Smart home and building
      • Space and aeronautics
      • Watchmaking
    • Tailored services
    • How to collaborate with us
    • IP policy and confidentiality
    • European projects
  • News & more
    • News
    • Events
    • Blog
  • Press and Publications
    • Press room
    • Downloads
    • YODA Open access platform
HomepagePress and PublicationsPressORGANTRANS
February 4, 2020

ORGANTRANS

European (EU) H2020 funded ORGANTRANS project is set to develop a disruptive solution that enables the 3D printing of tissue-engineered constructs. Coordinated by CSEM, eight consortium members will create a standardized and automated tissue preparation and maturation platform, which will provide patients with End-Stage Liver Disease (ESLD) an alternative to donor organ transplants.

Organtrans - new regenerative therapy
Press release

Related Press

A hand holding a bioreactor to grow vein grafts developed by CSEM and ClexBio

22 February 2024

CSEM and ClexBio create a bioreactor for tissue-engineered cardiovascular implants

The teams at CSEM and at ClexBio have developed a process for engineering vein grafts comprised of human tissue material that integrates into the patient’s body and can turn into real, living tissue....

Limula team

3 February 2023

Making personalized cancer therapies accessible to all

CSEM has supported Lausanne-based start-up Limula in its mission to make cell therapies more affordable, and to facilitate access to these personalized treatments. ...

Customized skin tissue grafts

24 June 2021

CUTISS

CUTISS AG, a Swiss clinical-stage life sciences company focused on skin regenerative medicine and tissue engineering, has unveiled the world’s first automated machine to produce customized skin tissue...

CSEM SA, Rue Jaquet-Droz 1, 2000 Neuchâtel

© 2026 CSEM SA

Legal noticePrivacy policyCookie policy